[{"address1": "11400 West Olympic Boulevard", "address2": "Suite 200", "city": "Los Angeles", "state": "CA", "zip": "90064", "country": "United States", "phone": "310 651 8041", "website": "https://www.immixbio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.", "fullTimeEmployees": 14, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ilya  Rachman M.B.A., M.D., MBA, Ph.D.", "age": 50, "title": "Co-Founder, CEO & Chairman", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 669000, "exercisedValue": 0, "unexercisedValue": 1846232}, {"maxAge": 1, "name": "Mr. Gabriel  Morris B.A.", "age": 36, "title": "CFO & Director", "yearBorn": 1987, "fiscalYear": 2023, "totalPay": 669000, "exercisedValue": 0, "unexercisedValue": 3188312}, {"maxAge": 1, "name": "Mr. Nandan  Oza B.S.", "age": 61, "title": "Head of Chemistry, Manufacturing & Control", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Marks", "title": "Chief Medical Officer of Cell Therapy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gerhard  Bauer", "title": "Head of Cell Thearpy Manufacturing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.24, "open": 2.25, "dayLow": 2.11, "dayHigh": 2.2799, "regularMarketPreviousClose": 2.24, "regularMarketOpen": 2.25, "regularMarketDayLow": 2.11, "regularMarketDayHigh": 2.2799, "beta": 0.236, "forwardPE": -2.158416, "volume": 124402, "regularMarketVolume": 124402, "averageVolume": 186301, "averageVolume10days": 106910, "averageDailyVolume10Day": 106910, "bid": 2.09, "ask": 2.23, "bidSize": 100, "askSize": 100, "marketCap": 57560940, "fiftyTwoWeekLow": 1.4, "fiftyTwoWeekHigh": 7.75, "fiftyDayAverage": 2.7424, "twoHundredDayAverage": 3.521975, "currency": "USD", "enterpriseValue": 39832668, "floatShares": 14092521, "sharesOutstanding": 26404100, "sharesShort": 349888, "sharesShortPriorMonth": 316557, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.013300001, "heldPercentInsiders": 0.45896998, "heldPercentInstitutions": 0.088120006, "shortRatio": 2.37, "shortPercentOfFloat": 0.0179, "bookValue": 0.823, "priceToBook": 2.6488457, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -15426048, "trailingEps": -0.89, "forwardEps": -1.01, "enterpriseToEbitda": -2.469, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "IMMX", "underlyingSymbol": "IMMX", "shortName": "Immix Biopharma, Inc.", "longName": "Immix Biopharma, Inc.", "firstTradeDateEpochUtc": 1639665000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a16f90b7-2d1a-3bc1-ad13-b52d1a275ae3", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.18, "targetHighPrice": 14.0, "targetLowPrice": 14.0, "targetMeanPrice": 14.0, "targetMedianPrice": 14.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 17509792, "totalCashPerShare": 0.663, "ebitda": -16135645, "quickRatio": 5.02, "currentRatio": 5.317, "returnOnAssets": -0.57923, "returnOnEquity": -1.06225, "freeCashflow": -5937478, "operatingCashflow": -11371438, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-10"}]